| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a799d17d5f808bee28dc9a15345a54f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2017-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23cf8cbf977c05beb154a262e900b29f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6b3eb3561524efa2868aa46dba62783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c53a22ecc9091c8db984a30e3bc9926
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_591b4ff806c6ac50610adbeabf12ce05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9334d6d396c199f51b2a83b5b0ae25b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8064977f49233020fe5a1baf93825aac |
| publicationDate |
2019-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3500253-A1 |
| titleOfInvention |
Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors |
| abstract |
The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H 3 R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination. |
| priorityDate |
2016-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |